ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Decreased Cancer Susceptibility in Tolerant Liver Transplant Recipients: Another Benefit of Tolerance?

M. P. Bhat1, E. Pasini1, C. Baciu1, S. M. Kurian2, J. Levitsky3

1Multi-Organ Transplant, UHN, Toronto, ON, Canada, 2Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, 3Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2019 American Transplant Congress

Abstract number: 150

Keywords: Gene expression, Hepatocellular carcinoma, Sirolimus (SLR), Tolerance

Session Information

Session Name: Concurrent Session: Liver Transplant Oncology

Session Type: Concurrent Session

Date: Sunday, June 2, 2019

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:30pm-5:42pm

Location: Room 311

*Purpose: Long-term survival of transplant recipients is significantly impacted by malignancy. Induction of tolerance is feasible in a subset of liver transplant (LT) recipients. The aim of our study was to determine whether patients weaned off immunosuppression have favorable changes in their molecular profiles in regard to malignancy risk.

*Methods: Liver transplant (LT) recipients having undergone direct conversion from tacrolimus to sirolimus monotherapy, followed by successful weaned off of sirolimus at a later date (tolerance), were included. Gene expression profile on the whole blood was performed with Affymetrix HT HG-U133 Plus PM platform at the three time points. Key dysregulated genes, their overlap with hepatocellular carcinoma (HCC), colon cancer and Hodgkin Lymphoma (HL) datasets from Gene Expression Omnibus (GEO) and pathway enrichment analysis were obtained.

*Results: Twenty non-immune, non-viremic patients (age 57.2±8; 3.5±2.1 years post-LT)were included and eight of them achieved tolerance. Two independent analyses were performed 1) sirolimus conversion vs tacrolimus monotherapy, 2) tolerance time point vs sirolimus. Genes identified as dysregulated in each analysis were identified as affected in HCC, colon and HL but frequently with an opposite modulation, in particular compared to HCC (Figure 1A, C, D). These genes were involved in cell cycle (FDR p-value 2.28 e-12), DNA replication (FDR p-value 3.02e-10) and mitotic phase transition (FDR p value 1.85e-25). Figure 1: Overlap of the dysregulated genes affected at the different time points with HCC, colon cancer and HL and their protein-protein interactions obtained by STRING. Genes affected by conversion from tacrolimus to sirolimus (A,B), and sirolimus to tolerance (C,D) were identified.

 border=

*Conclusions: This unique longitudinal study of patients progressing from tacrolimus to sirolimus, and finally to tolerance reveals a potential added benefit to achieving tolerance, i.e. decreased cancer susceptibility on the basis of favorable changes in their molecular profiles. Future validation will include assessment as to whether these gene expression patterns predict reduced malignancy risk in patients who achieve tolerance.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Bhat MP, Pasini E, Baciu C, Kurian SM, Levitsky J. Decreased Cancer Susceptibility in Tolerant Liver Transplant Recipients: Another Benefit of Tolerance? [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/decreased-cancer-susceptibility-in-tolerant-liver-transplant-recipients-another-benefit-of-tolerance/. Accessed May 29, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences